Tada H, Kagawa K, Hikita H, Takeuchi T, Ohta Y, Fukui S, Shintani H, Deguchi T, Okanoue T, Takino T
3rd Dept. of Int. Med. Kyoto Prefectural Univ. of Med.
Gan No Rinsho. 1989 Apr;35(5):564-70.
We have measured the plasma PIVKA-II levels in 188 cases of various liver disease with HCC and malignant diseases in other organs by an EIA, using a monoclonal antibody (E-1023 kit, Eisai), and also have measured the plasma vitamin K levels in cases of HCC and cholestasis by an HPLC. Plasma PIVKA-II was detected in many cases of HCC (67%, 35 of 52 cases) and cholestasis (60%, 6 of 10 cases). In contrast, the positivities of PIVKA-II in the other diseases including benign liver diseases were very low. Combination assays of PIVKA-II and vitamin K revealed that PIVKA-II correlates with vitamin K in cholestasis but not in HCC, suggesting that PIVKA-II in HCC does not depend on a systemic deficiency of vitamin K. From these results, it was concluded that PIVKA-II is a reliable marker which can reflect the clinical course of HCC.
我们使用单克隆抗体（卫材株式会社的E-1023试剂盒），通过酶免疫测定法（EIA）测定了188例患有肝癌的各种肝病患者以及其他器官恶性疾病患者的血浆异常凝血酶原-II（PIVKA-II）水平，并且还通过高效液相色谱法（HPLC）测定了肝癌和胆汁淤积患者的血浆维生素K水平。在许多肝癌病例（67%，52例中的35例）和胆汁淤积病例（60%，10例中的6例）中检测到了血浆PIVKA-II。相比之下，包括良性肝病在内的其他疾病中PIVKA-II的阳性率非常低。PIVKA-II和维生素K的联合检测显示，PIVKA-II在胆汁淤积中与维生素K相关，但在肝癌中不相关，这表明肝癌中的PIVKA-II并不依赖于维生素K的全身性缺乏。从这些结果得出结论，PIVKA-II是一种能够反映肝癌临床病程的可靠标志物。
